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ABSTRACT
Objectives: To update UK studies begun in the early
1990s on the annual prevalence and incidence rates of
autism in children; undertaken in response to a March
2012 press release, widely covered by the media, from
the US Centre for Disease Control (CDC) reporting that
the autism prevalence rate in 2008 in 8-year-old US
children was 1 in 88, a 78% increase from a CDC
estimate in 2004. This finding suggested a
continuation of the dramatic increase in children
diagnosed as autistic, which occurred in the 1990s.
Design: Population study using the UK General
Practice Research Database (GPRD).
Methods: Annual autism prevalence rates were
estimated for children aged 8 years in 2004–2010 by
dividing the number diagnosed as autistic in each or
any previous year by the number of children active in
the study population that year. We also calculated
annual incidence rates for children aged 2–8 years, by
dividing the number newly diagnosed in 2004–2010 by
the same denominators.
Results: Annual prevalence rates for each year were
steady at approximately 3.8/1000 boys and 0.8/1000
girls. Annual incidence rates each year were also
steady at about 1.2/1000 boys and 0.2/1000 girls.
Conclusions: Following a fivefold increase in the
annual incidence rates of autism during the 1990s in
the UK, the incidence and prevalence rates in 8-year-
old children reached a plateau in the early 2000s and
remained steady through 2010. Whether prevalence
rates have increased from the early 2000s in the USA
remains uncertain.
BACKGROUND
In March 2012, the US Centre for Disease
Control (CDC) issued a press release1 that
described the results of a long-term study on
the annual prevalence rate of autism in
8-year-old children.2 They reported that 1 of
88 children aged 8 years had been diagnosed
as autistic in or prior to 2008. This repre-
sented a 78% increase from the estimate in
2004. The press release received wide media
attention and prompted us to review and
update the information accrued in the UK
General Practice Research Database (GPRD)
over the past 20 years to derive annual preva-
lence rate estimates in children in the UK
for the years 2004–2010. For direct compari-
son with the CDC study, we restricted our
results to 8-year-old children.
METHODS
The GPRD is a unique longitudinal elec-
tronic medical database constructed and
implemented in 1990 through a combined
effort of the Boston Collaborative Drug
Surveillance Program (BCDSP), a UK
general practitioner (GP) who spent 5 years
creating a comprehensive electronic GP
ofﬁce medical record system to replace pre-
existing paper records, and a private
company, Vamp Health. The GPs who parti-
cipated used identical software and were
trained to enter medical information accord-
ing to a formal protocol. Some 1000 GPs in
over 300 general practices—about 5% of the
UK population—were enrolled by 1996. The
distribution of practices was designed to be
representative of the UK population. Our
programmer constructed a unique
ARTICLE SUMMARY
Strengths and limitations of this study
▪ This study is fully representative of the UK
general population.
▪ The UK General Practice Research Database
(GPRD) is a uniquely constructed resource of
clinical medical information that has succeeded
in providing a reliable continuous standardised
account of demographics, medical diagnoses
and prescribed medicines over more than
20 years. It is one of the largest sources of
primary care data in the world.
▪ There may have been unidentified cases (false
negatives) in the study population—individual
children with autism who were diagnosed else-
where and not notified to their general practi-
tioners or others who remained undiagnosed.
Taylor B, Jick H, MacLaughlin D. BMJ Open 2013;3:e003219. doi:10.1136/bmjopen-2013-003219 1
Open Access Research
 group.bmj.com on January 15, 2014 - Published by bmjopen.bmj.comDownloaded from 
comprehensive computer ﬁle structure that integrated
all the information into a uniﬁed resource that allowed
for rapid access to the full dataset, updated annually.
Early validation studies found an 87% correlation
between the diagnoses in consultant’s letters and those
in the GPRD record.3 The high quality, stability and con-
sistency of the recorded information over time has been
repeatedly demonstrated in more than 150 publica-
tions.4–11
Autism is a developmental disorder manifested early
in childhood and characterised by a spectrum of abnor-
mal social and communication skills and unusual behav-
iour. The condition was infrequently diagnosed prior to
1990. However, an awareness of a gradual increase in the
frequency of diagnosed autism was anecdotally noted
during the early 1990s. GPs themselves do not make the
diagnosis of autism, referring children suspected of
having the condition for specialist multidisciplinary
assessment, which usually takes place over a period of
months. Referral letters to GPRD-participating GPs from
consultants and others are scanned and diagnostic infor-
mation therein coded and recorded in the child’s clin-
ical record. The validity of the autism diagnosis
recorded by GPs was conﬁrmed in the earlier phases of
this study by review of the extensive specialist referral
reports.5 The quality and speciﬁcity of the diagnosis of
autism in the GPRD have also been validated by an inde-
pendent research group based on the Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition
(DSM-IV) criteria12 13; in 318 cases diagnosed with
autism or a related condition such as Asperger’s syn-
drome, the researchers, using specialist reports from
consultants or multidisciplinary teams in the GP record,
were able to conﬁrm the diagnosis for 294 (92.5%).
Annual prevalence rates were calculated by dividing
the number of children aged 8 years diagnosed as autis-
tic and recorded in the continuous medical record by
the GP at any time, by the number of 8-year-olds active
in the database that year. For example, prevalence rates
for 2004 were based on the number of children who
were aged 8 in 2004 and had been diagnosed as autistic
during the eight years 1996–2004. Continuous preva-
lence rates were similarly estimated for each subsequent
calendar year.
We also calculated annual incidence rates by dividing
the annual number of children aged 2–8 years newly
diagnosed with autism in each year (2004–2010), by the
number of children aged 2–8 years active in the prac-
tices in that year. Practices enrolled in the GPRD only
after 1996 were excluded from the study.
RESULTS
Table 1 shows the annual number of boys aged 8 years
who had been diagnosed as autistic in each or any previ-
ous year, that is, prevalent cases. The annual number of
prevalent cases (a reﬂection of the cumulative incidence)
is remarkably similar over calendar time, as is the number
of boys active in the population from 2004–2010. The
resulting annual prevalence rate estimates of about 3.8/
1000 boys are steady over time. The 95% conﬁdence limits
widely overlapped in each year.
Table 1 also shows the annual number of boys aged 2–
8 years diagnosed as autistic for the ﬁrst time (incident) in
each year from 2004–2010. The annual number of inci-
dent cases is again remarkably similar over time as is the
number of boys active in the practices each year, resulting
in annual incidence estimates of about 1.2/1000 boys over
the years. The total number of boys was 1190.
The number of girls initially diagnosed as autistic
from 2004–2010 was 217. Table 2 provides the annual
prevalence and incidence rate estimates over time for
girls. Girls were about one-ﬁfth as likely to be diagnosed
with autism as boys.
DISCUSSION
In the present paper we review and update an extraor-
dinary 20-year exploration of the annual rates of autism
in young children as recorded in real time and derived
from a unique carefully designed medical database in
the UK. In a series of formal analyses of the data
recorded continuously in the GPRD by some 1000 GPs,
we have documented that the cumulative incidence of
autism in children born from 1988 to 1995 began to
increase and continued to rise from a low level by more
than ﬁvefold during these years.14–16 The present study
demonstrates that the annual incidence then levelled off
and reached a steady state in children born from 1996
to 2001.
In order to compare the UK experience with that
reported by the CDC, we restricted our current preva-
lence study to annual calendar years 2004–2010 in chil-
dren 8 years of age. These children would have all been
born after 1995. Combined, the results in this 20-year
population-based UK resource, provide compelling evi-
dence that a major rise in incidence rates of autism,
recorded in general practice, occurred in the decade of
the 1990s but reached a plateau shortly after 2000 and
has remained steady through 2010. This incidence
plateau was necessarily accompanied by steady preva-
lence rates for 8-year-old children.
It is possible that at least a part of the early rise was
related to changing and broadening diagnostic criteria
to include a spectrum of disorders,17 18 as well as social
inﬂuences,19 including increased general medical and
public awareness.20 However, it seems unlikely that these
factors materially explain the extraordinary increase in
the number of children diagnosed in the 1990s; nor the
steady state that followed thereafter in 2004 through
2010. While the MMR vaccine was surely not the cause
of the dramatic rise in the 1990s, the actual cause
remains in large part a mystery.
For many years the terms incidence and prevalence
were applied in medicine primarily to describe acute
outbreaks of infectious diseases such as inﬂuenza,
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measles and mumps. Since the mid-1950s, these terms
have also been applied to chronic diseases such as dia-
betes, cancer and more recently autism. Even a superﬁ-
cial consideration of the use of these general terms will
reveal the complexity and subtlety of their application in
quantitative observational time trend studies in clinical
medicine.
The term ‘prevalence’ alone is used widely to describe
a general property possessed by an indeﬁnite quantity of
a condition, for example, the prevalence of conservative
voters is higher in rural compared to urban areas. It is
also used in public health as a general frequency or
quantity, for example, the prevalence of inﬂuenza is
higher in winter than in the summer.
In contrast, in formal epidemiological research, reli-
able quantitative estimates of incidence and prevalence
‘rates’ require accurate identiﬁcation of the number of
newly diagnosed cases in a deﬁned population from
which the cases were derived, at a given age during a
given time period. Valid comparisons of annual rate esti-
mates over many years are dependent on the stability of
the base population and the ascertainment of the condi-
tion under study.
In 1996, the CDC conducted a study based on screen-
ing and abstraction of records in the ﬁve counties of
Atlanta, Georgia.21 The prevalence was estimated to be
3.4 per 1000 among children aged 3–10 years. Surveys in
California in 1983–1985 and in 1993–1995 based on
birth cohorts22 23 found that during years 1980–1994
there was a large annual secular increase in the number
of cases of autism; these increases were estimated as a
prevalence of 44 per 100 000 live-births in the 1980
cohort and 208 in the 1994 cohort.24 A study from
Denmark estimated that the prevalence of autism rose
from less than 2 per 10 000 prior to 1990 to more than
10 per 10 000 in 2000.25 Taken together these reports
and others provided clear evidence that there was a sub-
stantial increase in the number of young children diag-
nosed as autistic in the USA and Europe during the
decade of the 1990s.
We could have estimated cumulative incidence and
annual prevalence rates for other age ranges, for
example, for 3-year-olds or 5-year-olds, from within the
GPRD dataset, but there are no other published studies
for comparison. Any comparisons of our results with
other published studies on autism frequencies do not
appear to be valid. There have been many studies inves-
tigating the prevalence of autism—in various countries
across the world, assessing different ages, durations and
varying calendar times.26 Few studies have been able to
assess cumulative incidence. Prevalence estimates have
varied from 2.8 to 94 for autistic disorder and 1 to 189
for ‘pervasive developmental disorders’.26 Recent studies
have tended to show higher prevalence rates.
Cohort effects have been identiﬁed27 as well as
marked spatial clustering.28 Reported numbers of cases
Table 1 Prevalence and incidence rates of boys aged 8 for years 2004–2010
Year
Number of boys
aged 8 years
in GPRD
Number of
prevalent
cases
Prevalence rate
per 1000 95% CI
Number of
incident
cases
Incidence rate
per 1000 95% CI
2004 145 483 521 3.58 3.28 to 3.80 172 1.18 1.01 to 1.37
2005 143 721 535 3.72 3.41 to 4.05 170 1.17 1.00 to 1.35
2006 147 049 568 3.86 3.56 to 4.19 190 1.29 1.12 to 1.49
2007 142 229 540 3.79 3.49 to 4.13 173 1.21 1.05 to 1.41
2008 138 847 543 3.91 3.59 to 4.25 170 1.22 1.05 to 1.42
2009 138 317 566 4.09 3.77 to 4.40 180 1.30 1.02 to 1.50
2010 132 143 515 3.90 3.57 to 4.24 135 1.02 0.86 to 1.20
GPRD, UK General Practice Research Database.
Table 2 Prevalence and incidence rates of girls aged 8 for years 2004–2010
Year
Number of
girls aged
8 years in
GPRD
Number of
prevalent
cases
Prevalence
rate per 1000 95% CI
Number of
incident
cases
Incidence
rate per 1000 95% CI
2004 136 752 109 0.80 0.66 to 0.96 27 0.20 0.14 to 0.28
2005 135 511 112 0.83 0.68 to 0.99 30 0.22 0.15 to 0.31
2006 138 548 112 0.81 0.69 to 0.97 34 0.25 0.17 to 0.39
2007 134 083 125 0.93 0.78 to 1.11 41 0.31 0.22 to 0.41
2008 130 876 107 0.82 0.67 to 0.98 29 0.21 0.14 to 0.29
2009 130 367 106 0.81 0.67 to 0.98 30 0.23 0.16 to 0.32
2010 124 135 101 0.81 0.67 to 0.99 26 0.21 0.14 to 0.30
GPRD, UK General Practice Research Database.
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in some studies have been low and have tended to vary
(eg, 86 children with autistic spectrum disorder (ASD)
at age 11 in the UK Avon study29 and 158 from a
screened population of 56 946 children age 9–10 years
in the UK Special Need and Autism Project30), with dif-
ferent studies showing widely varying proportions of sub-
groups of autism. Denominators have sometimes been
unclear.
Some studies have based their ﬁndings on ASD screen-
ing questionnaires, which typically misidentify substantial
numbers of children who have other difﬁculties, but not
an ASD.31 Using strict or less demanding diagnostic cri-
teria, even within a single study where design and meth-
odological factors are invariant, can affect prevalence
estimates by up to 4.5 times.32 There were some regional
variations in rates of recorded autism in the GPRD, pos-
sibly reﬂecting regional variation in diagnostic practice,
but rates within areas remained steady overall during the
study period. This was a real-life clinically based study, with
no attempt to screen the child population for autism.
Such screening may contribute to overdiagnosis.31
In February 1998, Wakeﬁeld et al33 reported a case
series of 12 autistic children with bowel disorders most
of whom had recently received the MMR vaccine. The
authors suggested that the MMR vaccine may have been
causally related to these gastrointestinal conditions. This
widely publicised paper led to subsequent studies to
evaluate the proposition that the MMR vaccine might be
causally related to autism.
In the following year, Taylor et al34 reported results
from a study based on birth cohorts from 1979–1992 in
the North East Thames (UK) health region. They
reviewed special needs records and found that fewer
than 10 children/year born from 1979 through 1986
were diagnosed as autistic. Subsequently, the number
increased to almost 50 in children born in 1992. They
found no correlation between MMR vaccination and the
rise in the prevalence of autism.
Shortly thereafter, the BCDSP examined experience
accrued in the GPRD since 1990 to estimate annual
cumulative incidence rates of autism for birth cohorts
from 1988–1993 for boys aged 2–5 years and found that
cumulative incidence rates increased some ﬁvefold from
an estimate of 6 per 10 000 in boys born in 1988 to 30
per 10 000 in those born in 1993. At the same time
MMR vaccination was given to over 90% of young chil-
dren ruling out an association between the vaccine and
the dramatic increase in rates.14
Subsequent studies also found no association between
MMR and autism.14 24 25 35 36 Lingam et al36 suggested
that the previously observed annual increase in preva-
lence in North-East London may have been levelling off
by the mid-1990s.
The BCDSP continued to assess time trends by updat-
ing the ﬁndings recorded in the GPRD for additional
birth cohorts. Results of birth cohorts from 1994 to 1995
continued to show a rise in the cumulative incidence of
diagnosed autism but results of 1996–1997 indicated
that the rise may have reached a plateau.15 Subsequent
follow-up demonstrated that rates had in fact plateaued
in the 1996 cohort and remained steady for 1996
through the 2001 birth cohort16 (see ﬁgure 1). Children
born in 2001 would have been diagnosed as autistic at
age 2–4 years in 2003–2005.
Taken together the published ﬁndings conclusively
demonstrated that there was a dramatic simultaneous
rise in the number of children diagnosed as autistic in
the USA, UK and Denmark during the 1990s. In add-
ition, there was highly persuasive evidence that MMR
vaccine was not the cause of the rise. Despite ﬁrm evi-
dence that a steady state occurred in children born from
1996 through 2001 in the UK, vaccine/autism litigation
continued in US courts until 2010.
The initial autism studies5 14–16 34–36 were based pri-
marily on birth cohorts usually aged 2–5 years. In that
design the number of newly diagnosed (incident) cases
is determined separately for each annual birth cohort.
In contrast, the nature and interpretation of annual
prevalence ‘rates’ of autism, as reported in the present
and the recent CDC studies, are far more complex and
superﬁcially counterintuitive, particularly where the
design objective is to estimate changes in yearly time
trends or to compare results with other similarly
designed studies.
The CDC chose to estimate annual prevalence rates
for children of the same age—8 years—in each of suc-
cessive calendar years. Annual prevalence estimates
apply to children who encompass a large age range, for
example, 2–8 years and each of the autism cases may be
included as prevalent in multiple years. For example,
when examining the period 2004–2010, a child diag-
nosed at age 2 years in 2004 would be included in the
prevalence estimate for each of the next 6 years until the
child reached age 9 years and no longer is considered a
prevalent case. Children diagnosed at age 6 in 2005
would be included in the prevalence estimates for only
Figure 1 Three-year cumulative incidence of diagnosed
autism among boys aged 2–4 years, in birth cohorts. Adapted
from Hagberg and Jick.16 Promotional and commercial use of
the material in print, digital or mobile device format is
prohibited without the permission from the publisher Lippincott
Williams & Wilkins. Please contact journalpermissions@lww.
com for further information.
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3 years thereafter. Year of age at ﬁrst diagnosis, including
prior to 2004, is thus a critical variable in estimating the
annual prevalence rates at age 8 over many years. The
full detail that yielded the annual prevalence rates could
be reviewed directly for consistency.
The 2012 CDC report2 was a follow-up to studies of
8-year-old children initiated in 2000 and repeated every
2 years thereafter. The results were derived from a network
of 6–11 US states depending on the years, and based on
school or medical records or both. Early reports estimated
annual prevalence rates of 6.7 and 6.6 per 1000 children
in 2000 and 2002, respectively. Starting in 2004, prevalence
rate estimates rose steadily until 2008 when they reached
11.3 per 1000, a rise of 78% from 2004. The latest preva-
lence rate estimates varied widely from state to state—from
4.1/1000 in Alabama to 21.2/1000 in Utah.
A detailed commentary on the limitations of the CDC
report was published shortly after it was released.37 This
commentary raised important questions related to the
accuracy and speciﬁcity of the combined rate estimates
over the years.
There are many similarities between the results found
in the USA and UK in the secular epidemiology of
autism. Few children were diagnosed as autistic in either
country prior to 1990. A continuous simultaneous extra-
ordinary rise in the number of children diagnosed as
autistic began in both countries in the early 1990s and
lasted for a decade. The distribution of ﬁrst time diagno-
sis according to age and gender was the same. These
similarities between countries as well as within different
locations in each country point to a common aetiology
for this extraordinary medical case.
In contrast, there is a large difference in the percent-
age of children diagnosed as autistic in the two coun-
tries. The estimated prevalence rates of autism in the
UK population, about 4 per 1000 in 8-year-old boys in
2008, is far lower than 11 per 1000 in 8-year-old boys
reported by the CDC from the USA for the same calen-
dar year. This large difference between countries is
closely similar to differences in rates reported for chil-
dren diagnosed and treated for attention deﬁcit hyper-
activity disorder in the two countries.38 39
The GPRD is a uniquely constructed resource of clin-
ical medical information that has succeeded in provid-
ing a reliable continuous standardised accounting of
demographics, medical diagnoses and prescribed medi-
cines over more than 20 years. The substance of its con-
struction and implementation is highly complex.
Nowhere is this clearer than in the current ﬁndings
related to the enormously complex secular epidemiology
of autism.
In conclusion, the annual prevalence of clinically con-
ﬁrmed autism recorded by UK GPs remained steady for
the 7-year period 2004–2010. Whether it has increased
in the USA over these years remains uncertain.
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